Trial Profile
International Study to Predict Optimised Treatment - in Depression.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Escitalopram (Primary) ; Sertraline (Primary) ; Venlafaxine (Primary)
- Indications Major depressive disorder
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Acronyms iSPOT-D
- Sponsors BRC Operations
- 29 Oct 2020 This trial has been Discontinued in Netherlands, according to European Clinical Trials Database record.
- 09 Jul 2018 Planned End Date changed from 1 Apr 2018 to 1 Dec 2019.
- 09 Jul 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.